About zentalis pharmaceuticals inc - ZNTL
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
ZNTL At a Glance
Zentalis Pharmaceuticals, Inc.
10275 Science Center Drive
San Diego, California 92121
| Phone | 1-858-263-4333 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -137,060,000.00 | |
| Sector | Health Technology | Employees | 106 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ZNTL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.431 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.751 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.362 |
ZNTL Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,293,018.868 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ZNTL Liquidity
| Current Ratio | 6.926 |
| Quick Ratio | 6.926 |
| Cash Ratio | 6.726 |
ZNTL Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -38.109 |
| Return on Equity | -49.535 |
| Return on Total Capital | -53.585 |
| Return on Invested Capital | -43.603 |
ZNTL Capital Structure
| Total Debt to Total Equity | 18.305 |
| Total Debt to Total Capital | 15.473 |
| Total Debt to Total Assets | 13.696 |
| Long-Term Debt to Equity | 16.514 |
| Long-Term Debt to Total Capital | 13.959 |